Comparative Pharmacology
Head-to-head clinical analysis: BUTALAN versus ESGIC PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALAN versus ESGIC PLUS.
BUTALAN vs ESGIC-PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalan is an ergot alkaloid derivative that acts as a partial agonist at serotonin (5-HT2B) receptors and an antagonist at alpha-adrenergic and dopamine (D2) receptors. It also inhibits prolactin secretion by stimulating dopamine receptors in the pituitary.
Esgic-Plus is a combination of acetaminophen (analgesic/antipyretic via COX inhibition and central action), butalbital (barbiturate that enhances GABA-A receptor activity), and caffeine (adenosine receptor antagonist and CNS stimulant). The mechanism for treating tension headache is attributed to the synergistic effects of these components.
1-2 tablets (50-100 mg butalbital, 325-650 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not exceeding 6 tablets per day.
1-2 capsules (acetaminophen 500 mg, butalbital 50 mg, caffeine 40 mg per capsule) orally every 4 hours as needed, not exceeding 6 capsules per day.
None Documented
None Documented
4-6 hours (terminal); prolonged in renal impairment (up to 12-15 hours)
Butalbital: 35-70 hours in adults; prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours in adults; extended in overdose (potential hepatotoxicity). Caffeine: 3-6 hours in adults; increased in pregnancy or liver disease.
Primarily renal (70% unchanged, 20% as metabolites); fecal 10%
Butalbital: 60-90% renal as unchanged drug and metabolites, 10-40% fecal via biliary elimination. Acetaminophen: ~85% renal as glucuronide (45-55%), sulfate (25-35%), and cysteine conjugates (4-15%); 2-4% unchanged. Caffeine: ~85-90% renal as metabolites (1-methylxanthine, 1-methyluric acid, 1,7-dimethylxanthine); 1-3% unchanged.
Category C
Category C
Barbiturate
Barbiturate/Narcotic Combination